Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rPSGL-Ig
- Development stage
- Phase 2
- Lead developer
- Thios Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a recombinant fusion protein composed of the human P-selectin glycoprotein ligand 1 (PSGL-1) fused to the Fc region of human immunoglobulin G1. It acts as a selectin antagonist, blocking leukocyte adhesion by binding to selectins and thereby inhibiting neutrophil entry into inflamed or ischemic tissues. This mechanism reduces inflammatory responses and tissue injury, particularly in settings such as transplantation ischemia-reperfusion injury and myocardial infarction. The drug has been investigated for use in conditions including myocardial infarction, delayed graft function after organ transplantation, glomerulonephritis, anemia, red blood cell disorders, and kidney transplant surgery[1][2][4][6][8].
- Brand names
- Torapsel
- Other names
- Recombinant P-selectin glycoprotein ligand-immunoglobulin IgRecombinant soluble PSGL-1 Fc chimera
02
Targets
SELP (P-selectin)SELE (E-selectin)SELL (L-selectin)
Beyond the preview
Go deeper on rPSGL-Ig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rPSGL-Ig.